Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Larazotide acetate in celiac disease
NCT01396213Phase 2Completed
- Sponsor
- Innovate Biopharmaceuticals
- Start
- Nov 2011
- Primary completion
- Aug 2013
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of larazotide in celiac disease (4 arms), sponsored by Innovate Biopharmaceuticals. Primary endpoint: Celiac Disease Gastrointestinal Symptom Rating Scale at 12 weeks. Started Nov 2011; status: completed.
02
Drugs
larazotide
03
Conditions
celiac disease
Beyond the preview
Go deeper on NCT01396213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01396213.